Regeneron (REGN) shares are down $36.88, or 5% to $660 in pre-market trading following the company’s update issued ahead of its planned presentation at the annual J.P. Morgan Healthcare Conference later this evening.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron reports preliminary Q4 Eylea HD U.S. net product sales of $305M
- Regeneron Highlights Growth and Innovation at Conference
- Regeneron reports ‘positive’ results from Phase 3 C-POST trial
- Regeneron announces strategic collaboration with Truveta
- Regeneron price target lowered to $950 from $1,000 at Oppenheimer